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Objectives. The purpose of this study was to determine if early
triage angiography with revascularization, if indicated, favorably
affects clinical outcomes in patients with suspected acute myocar-
dial infarction who are ineligible for thrombolysis.
Background. The majority of patients with acute myocardial
infarction and other acute coronary syndromes are considered
ineligible for thrombolysis and therefore are not afforded the
opportunity for early reperfusion.
Methods. This multicenter, prospective, randomized trial eval-
uated in a controlled fashion the outcomes following triage
angiography in acute coronary syndromes ineligible for thrombo-
lytic therapy. Eligible patients (n 5 201) with <24 h of symptoms
were randomized to early triage angiography and subsequent
therapies based on the angiogram versus conventional medical
therapy consisting of aspirin, intravenous heparin, nitroglycerin,
beta-blockers, and analgesics.
Results. In the triage angiography group, 109 patients under-
went early angiography and 64 (58%) received revascularization,
whereas in the conservative group, 54 (60%) subsequently under-
went nonprotocol angiography in response to recurrent ischemia
and 33 (37%) received revascularization (p 5 0.004). The mean
time to revascularization was 27 6 32 versus 88 6 98 h (p 5
0.0001) and the primary endpoint of recurrent ischemic events or
death occurred in 14 (13%) versus 31 (34%) of the triage angiog-
raphy and conservative groups, respectively (45% risk reduction,
95% CI 27–59%, p 5 0.0002). There were no differences between
the groups with respect to initial hospital costs or length of stay.
Long-term follow-up at a median of 21 months revealed no
significant differences in the endpoints of late revascularization,
recurrent myocardial infarction, or all-cause mortality.
Conclusions. Early triage angiography in patients with acute
coronary syndromes who are not eligible for thrombolytics re-
duced the composite of recurrent ischemic events or death and
shortened the time to definitive revascularization during the index
hospitalization. Despite more frequent early revascularization
after triage angiography, we found no long-term benefit in cardiac
outcomes compared with conservative medical therapy with revas-
cularization prompted by recurrent ischemia.
(J Am Coll Cardiol 1998;32:596–605)
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In the past decade, advances in terms of mortality reduction
have been made in the treatment of acute transmural myocar-
dial infarction with aspirin, beta-blockers and reperfusion
therapy with thrombolytics or primary angioplasty (1–13).
Unfortunately, similar inroads have not been made with re-
spect to other acute coronary syndromes, including nontrans-
mural infarctions and transmural infarctions that are not
eligible for reperfusion therapy (14). In fact, several lines of
evidence indicate thrombolytic therapy is ineffective or poten-
tially harmful in patients without classic electrocardiographic
(ECG) findings of transmural infarction (15–25). Retrospec-
tive reviews have shown the in-hospital mortality for those who
are not eligible for thrombolysis or reperfusion to be twofold
greater over those eligible and treated with reperfusion ther-
apy (26,27). Recent studies have indicated that patients with
acute coronary syndromes and evidence of myonecrosis from
sensitive enzymatic markers without elevations of creatine
kinase (CK) have a conferred increased risk of death over the
next 30 d irrespective of revascularization status (28–32).
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These findings imply that preempting ischemic events rather
than acting after they have occurred may be important in
reducing morbidity and mortality in those patients who are not
candidates for reperfusion therapy. Our study was designed to
define the role of early, catheterization-based therapy in
patients with acute coronary syndromes who are deemed likely
to be suffering from acute myocardial infarction (AMI), but
are ineligible for thrombolysis based on either the lack of
classic ECG changes or the presence of contraindications to
thrombolytics. We hypothesized that triage angiography with
early revascularization, when indicated, could reduce recurrent
ischemic events and death.
Methods
Patient selection. This study was approved by the Human
Investigations Committees at the four participating Southeast
Michigan community hospitals and subjects gave informed
consent. William Beaumont Hospital in Royal Oak and Prov-
idence Hospital in Southfield provided 24-h angiography and
angioplasty service with bypass surgery programs. Botsford
Hospital in Farmington Hills, and Riverside Hospital in Tren-
ton, offered angiography during working hours and referred
patients to the larger centers for off-hours angiography, angio-
plasty and bypass surgery. Subjects were those patients 18
years and older who presented to the emergency department
with an acute chest pain syndrome consistent with AMI (high
clinical suspicion for AMI with or without immediate enzy-
matic confirmation) and who were considered ineligible for
thrombolysis because of a lack of diagnostic ECG changes,
symptoms lasting longer than 6 h or because of increased
bleeding or stroke risks. None of these inclusion criteria
mandated entry into the trial. They were designed to provide
clinicians with categories to characterize patients during the
clinical judgment for thrombolytic eligibility. The inclusion
criteria allowed for a spectrum of ECG changes, as illustrated
in Table 1. Exclusion criteria were symptoms lasting for more
than 24 h or an absolute indication or contraindication to
cardiac catheterization.
Randomization and treatment. After informed consent
was obtained, patients were randomized according to a
computer-generated scheme and cards placed in sealed, or-
dered envelopes. Protocol guidelines called for all patients
to be treated with 325 mg of chewed aspirin, heparin
5,000–10,000 U intravenous (IV) bolus, followed by a 10
U/kg/h infusion, IV nitroglycerin 10–30 mg/min initially and
then titrated, and IV metoprolol up to 15 mg or IV propranolol
up to 8 mg as tolerated to achieve a heart rate , 70. Subjects
randomized to the conservative arm were then admitted to a
monitored bed and received continued medical therapy and
noninvasive evaluation encouraged by the protocol. There
were no mandated noninvasive tests or schedules in the
conservative arm. Criteria for crossover to a nonprotocol
catheterization in the first 24 h were persistent pain despite
maximal medical therapy .4 h in duration, recurrent pain with
ECG changes once pain free or hemodynamic instability.
Beyond the 24-h window, subjects underwent catheterization
based on ischemic events or physician preference, which was
representative of the standard care at the individual institution.
Subjects randomized to triage angiography were taken as soon
as possible directly to the catheterization laboratory from the
emergency department. All triage angiography patients under-
went catheterization within 24 h of arrival to the hospital. The
protocol encouraged decision making based on the angiogram
and discouraged additional noninvasive testing. Subjects with
an identifiable culprit lesion and suitable anatomy underwent
mechanical revascularization with percutaneous transluminal
coronary angioplasty (PTCA), atherectomy or stenting as
decided by the operator. All cases referred for coronary artery
bypass graft surgery (CABG) had the operation performed on
the index hospitalization. Early discharge was encouraged in
both groups.
Long-term follow-up was carried out by trained telephone
interviewers blinded to the randomization arm. Subjects un-
derwent a structured questionnaire at a median time of 21
months (12 months minimum and 52 months maximum) after
the index hospitalization. Twelve subjects, unable to be con-
tacted, were submitted to the National Center for Health
Statistics National Death Index for vital status at a minimum of
1 year after the index event.
Statistical analysis. Intention-to-treat principles were
used. Univariate statistics were reported as proportions or
means and comparisons were made with chi-square, Fisher’s
exact test, Kruskal-Wallis H-test and analysis of variance
(ANOVA) as appropriate. The primary composite endpoint of
recurrent ischemic events or death was evaluated with absolute
proportions and the calculated percent risk reduction with
95% exact mid-p confidence intervals. The number needed to
treat was calculated as the reciprocal of the absolute risk
reduction (33). Secondary endpoints including length of stay
(LOS) and hospital costs were compared using ANOVA,
chi-square for proportions and Fisher’s exact test as appropri-
ate. Outliers for both LOS and cost were excluded if they were
more than 2 standard deviations from the mean of the parent
distribution. True hospital costs, given in 1995 dollars, were
determined from internal accounting programs at William
Beaumont Hospital and from the hospital Medicare cost-to-
charge ratio at the other three hospitals. Reliable physician
cost data were not available. For patients who had stays at two
hospitals, LOS and costs were combined from the two facili-
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft surgery
CHF 5 congestive heart failure
CK 5 creatine kinase
LOS 5 length of hospital stay
MI 5 myocardial infarction
NIDDM 5 non-insulin–dependent diabetes mellitus
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in myocardial infarction
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ties. The sample size calculation of 225 in each arm was based
on an expected rate of the composite endpoint of 40%, an
effect size of 30% (absolute reduction), 1-b of 0.80 and a of
0.05 two-tailed. At 201 patients, one interim analysis was
performed with the randomization being unblocked, yielding
111 in the triage angiography arm and 90 in the conservative
arm. Because multiple hospitals were used, and each had sets
of randomization cards in sealed envelopes that were not equal
at set enrollment points, the study ended with unequal num-
bers in each group. Statistical significance was chosen at the
a , 0.05 level. Survival analysis was performed using Kaplan-
Meier curves and the log rank test for differences between the
randomization arms.
Variables and definitions. Acute myocardial infarction was
defined as a characteristic rise in total CK and myocardial
bands (MB) in the serum with the peak CK . 3.8 mkat/L
(230 U/L) in males, and CK . 2.5 mkat/L (150 U/L) in females,
and an MB index (MB fraction ng/ml/total CK U/L 3 100)
. 3% in both sexes. Recurrent ischemia was defined as chest
discomfort with or without ECG or hemodynamic changes, or
reinfarction. Angioplasty success was defined as ,50% resid-
ual lesion stenosis and thrombolysis in myocardial infarction
(TIMI) grade III flow in the culprit vessel. These outcomes
were determined prospectively, during the hospital stay, by an
independent research nurse and all ECGs were over-read by a
blinded physician (P.A.M.). Stroke was defined as a confirmed
complication by a neurologic consultant’s clinical evaluation.
Transient azotemia was considered as a rise in serum creati-
nine .25% over the baseline value. A bleeding complication
was defined as any bleeding event that required at least one
transfusion of red blood cells. A vascular complication was
defined as any catheter-related vascular injury requiring vas-
cular surgical repair. Revascularization included any type of
percutaneous intervention such as PTCA, atherectomy or
stenting and CABG.
Results
Baseline characteristics. Baseline characteristics for the
randomization arms are given in Table 1. The randomization
Table 1. Baseline Characteristics
Characteristic
Triage Angiography
Group (n 5 111)
Conservative
Group (n 5 90) p Value
Mean age (years) 57 61 0.07
Females/males 34:77 38:52 0.09
Chronic stable angina 30 (27%) 27 (30%) 0.64
Prior myocardial infarction 23 (21%) 20 (22%) 0.80
Prior coronary artery bypass surgery 10 (9%) 9 (10%) 0.81
Prior congestive heart failure 3 (3%) 2 (2%) 0.81
Insulin-dependent diabetes mellitus 2 (2%) 4 (4%) 0.49
Non–insulin-dependent diabetes mellitus 10 (9%) 20 (22%) 0.009
Current smoker 23 (21%) 18 (20%) 0.90
Ex-smoker 4 (4%) 17 (19%) 0.0004
Family history of premature CAD* 39 (35%) 30 (34%) 0.79
Dyslipidemia† 39 (35%) 44 (49%) 0.05
Peripheral vascular disease‡ 6 (5%) 5 (6%) 0.85
Cerebrovascular disease§ 7 (6%) 5 (6%) 0.82
ECG Feature
ST Segment elevation 36 (32%) 25 (28%) 0.48
ST Segment depression 24 (22%) 23 (26%) 0.51
T-wave inversion 49 (44%) 37 (41%) 0.67
Q-waves 26 (23%) 23 (26%) 0.73
Left bundle branch block 4 (4%) 5 (6%) 0.73
Right bundle branch block 5 (5%) 4 (4%) 0.75
Normal 22 (20%) 17 (19%) 0.87
Reason for Thrombolytic Exclusion
Ineligible by ECG 85 (77%) 74 (83%) 0.33
Symptoms .6 h in duration 55 (50%) 38 (43%) 0.30
Increased bleeding risk 5 (5%) 5 (6%) 0.81
Advanced age 7 (6%) 7 (8%) 0.68
Increased stroke risk 7 (6%) 6 (7%) 0.92
Symptoms had resolved 17 (15%) 8 (9%) 0.17
Uncontrolled hypertension 6 (5%) 3 (3%) 0.70
Limited infarction 2 (2%) 6 (7%) 0.16
*Indicates at least one first-degree relative with known coronary artery disease before the age of 55 years. †Indicates
a personal history of known elevated cholesterol or treated dyslipidemia. ‡Indicates a history of claudication or prior
peripheral artery angioplasty or surgical bypass procedure. §Indicates a prior history of transient ischemic attack or stroke
(either ischemic or hemorrhagic). Patients may have had more than one reason for thrombolytic ineligibility.
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held for all baseline characteristics except for a history of
non–insulin-dependent diabetes mellitus (NIDDM) (9% vs.
22%) and a history of previous smoking (4% vs. 19%), both of
which were more prevalent in the conservative group (p 5
0.009 and p 5 0.0004, respectively). There were no significant
differences between the groups with respect to presentation
features or reasons for reperfusion ineligibility. The mean time
from symptom onset to study entry was 9 6 7 h versus 9 6 6 h,
p 5 0.53, for the triage angiography and conservative groups,
respectively. Of note, 36 (22%) and 25 (28%) of the triage
angiography and conservative groups, respectively, presented
with ST segment elevation, which was persistent in 14 (13%)
and eight (9%). The distribution of cases by time to emergency
department presentation in the ST elevation subgroup was as
follows: within 6 h of symptoms, 24 versus 14; between 6 and
12 h, three versus six; between 12 and 24 h, seven versus five;
and greater than or equal to 24 h, two versus zero, for the
triage angiography and conservative groups, respectively. Irre-
spective of the time to presentation, the patients with ST
segment elevation had an average of 1.8 contraindications to
thrombolysis. This compares with the whole study population,
which had an average of 1.6 contraindications to thrombolysis.
Medical and interventional treatment. Proportions and
types of medical, interventional and surgical therapy received
by the patient groups are depicted in Table 2. Patient flow and
revascularization outcomes are depicted in Figure 1. Overall,
64 of 111 (58%) versus 33 of 90 (37%), p 5 0.004, in the triage
angiography and conservative groups, respectively, received
revascularization therapy. Of those who underwent catheter-
ization, each group had similar findings with respect to the
proportion of patients revascularized after the angiogram 64
of 109 (59%) versus 33 of 54 (61%), p 5 0.77. Of these 54
angiography cases in the conservative group, 27 (50%) under-
went the procedure because of ischemia-driven events such as
Figure 1. Flow diagram of 201 patients with acute coronary syndromes
randomized to conservative care or early triage angiography. Protocol
adherence was 98%, with 88 of 90 conservative group patients receiv-
ing medical care only and 109 of 111 triage group patients undergoing
angiography within the first 24 h of hospital admission.
Table 2. Initial Treatment Received and Complications Observed
Treatment
Triage
Angiography
Group (n 5 111)
Conservative
Group (n 5 90) p Value
Time to Treatment
Symptom onset to ED* arrival (h) 9 6 6 9 6 7 0.53
Symptom onset to angiography (h) 16 6 14 (n 5 109) 84 6 92 (n 5 54) , 0.0000001
Symptom onset to PTCA (h) 25 6 28 (n 5 48) 90 6 110 (n 5 27) 0.09
Symptom onset to CABG (h) 65 6 54 (n 5 18) 116 6 40 (n 5 7) 0.03
Medical Therapy
Aspirin 109 (98%) 88 (98%) 0.77
Beta blockers 63 (57%) 63 (70%) 0.05
Heparin IV 106 (96%) 89 (99%) 0.31
Nitroglycerin IV 106 (96%) 86 (96%) 0.75
Interventional Treatment
Triage angiography , 24 h 109 (98%) 2 (2.2%) ®†
PTCA performed 48 (43%) 27 (30%) 0.05
PTCA procedural success 46/48 (96%) 25/27 (93%) 0.88
CABG 18 (16%) 7 (8%) 0.07
Any revascularization 64 (58%) 33 (37%) 0.003
Complications
Transfusions 11 (10%) 4 (5%) 0.14
Stroke 2 (2%) 2 (2%) 0.77
Transient azotemia 2 (2%) 3 (3%) 0.80
Vascular surgical repair 1 (1%) 0 (0%) 0.55
*Indicates emergency department. †®Signifies the variable upon which the randomization was carried out.
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persistent or recurrent chest discomfort, hemodynamic com-
plications or positive exercise treadmill test results. The re-
mainder underwent the procedure as part of the physician’s or
patient’s preference. There was no difference in the composite
endpoint of in-hospital recurrent ischemic events or death in
the physician-preference versus protocol or ischemia-driven
angiography groups (4 of 27 [15%] vs. 29 of 136 [21%], p 5
0.52).
Of the 163 patients who ultimately underwent angiography,
the triage angiography and conservative groups were similar
with respect to the extent of disease and to the location of the
culprit lesion with the exception of the circumflex system
(Table 3). There were less circumflex or obtuse marginal
culprit lesions in the triage angiography arm (10 [9%] vs. 11
[20%], p 5 0.05). There were no differences between the mean
percent stenosis of the culprit lesion or the number of occluded
culprits between the randomization groups, with overall 33 of
163 cases (20%) having an occluded vessel at the time of
angiography.
Myocardial infarction, in-hospital recurrent ischemic
events and death. Acute myocardial infarction was confirmed
in 57 (51%) and 49 (54%) of the triage angiography and
conservative groups, respectively (p 5 0.81) (Table 4). Of
those with AMI, there were no differences between peak CK
values (16 6 22 mkat/L vs. 14 6 16 mkat/L and 962 6 1,339 U/L
vs. 835 6 963 U/L, p 5 0.47). Suspected acute MI was used as
an inclusion criteria into the trial and the initial rise in CK was
not included in any study endpoint. There were no differences
between the groups with respect to reinfarction or death (3
[3%] vs. 3 [3%], p 5 0.5). However, the expanded aggregate of
chest pain with ECG or hemodynamic changes, reinfarction or
death occurred in 5 (5%) and 12 (13%) of the triage angiog-
raphy and conservative groups, respectively (40% risk reduc-
tion, 95% CI 15–58%, p 5 0.03). Similarly, the composite
endpoint of all recurrent ischemic events or death occurred in
14 (13%) and 31 (34%), yielding a 45% risk reduction (95% CI
27–59%, p 5 0.0002), and the number needed to treat of five
patients to prevent one composite endpoint.
Hospital length of stay and costs. Economic endpoints of
LOS and cost are given in Table 4. There were no differences
in mean LOS between the groups after adjustment for outliers.
However, 39 (35%) versus 15 (17%) of the triage angiography
and conservative groups, respectively, were discharged in 2 or
less days (p 5 0.003). Similarly, of those who underwent
PTCA, 36 of 48 (75%) versus 13 of 27 (48%) were discharged
in 5 or less days (p 5 0.02); and of those who underwent
Table 3. Angiographic Findings of 163 Patients who Underwent Angiography on the
Index Hospitalization
Angiographic Finding
Triage Angiography
Group (n 5 109)
Conservative
Group (n 5 54) p Value
Extent of Disease
Single vessel disease 30 (28%) 14 (26%) 0.82
Multivessel disease* 44 (40%) 27 (50%) 0.24
Noncritical disease† 10 (9%) 5 (9%) 0.83
Normal coronaries 18 (16%) 8 (15%) 0.71
Mean percent stenosis of culprit 94 6 10 (n 5 54) 91 6 13 (n 5 36) 0.22
Occluded culprit lesions 22 (20%) 11 (20%) 0.98
Culprit vessel(s) location
Left main 2 0 —
LAD and branches‡ 20 (18%) 12 (22%) 0.56
Proximal LAD 10 9 —
Mid LAD 8 1 —
Distal LAD 1 0 —
Diagonal 1 2 —
LCX and branches 10 (9%) 11 (20%) 0.05
Proximal LCX 1 1 —
Mid LCX 3 2 —
Distal LCX 0 1 —
Obtuse marginal 6 7 —
RCA and branches 21 (19%) 12 (22%) 0.66
Proximal RCA 12 3 —
Mid RCA 2 5 —
Distal RCA 2 2 —
PDA 3 2 —
Other
SVG 2 0 —
Multiple culprits 1 1 —
*Indicates $ vessels with 70% stenosis or greater or significant left main disease. †Indicates ,70% stenosis, not
requiring intervention. ‡LAD 5 left anterior descending artery, LCX 5 left circumflex artery, RCA 5 right coronary
artery, PDA 5 posterior descending artery (considered a branch of RCA for classification purposes).
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CABG, 12 of 18 (67%) versus 1 of 7 (14%) were discharged in
10 or less days (p 5 0.03).
A comparison of mean hospital costs in 1995 dollars is given
in Table 4. The overall cost for all 201 patients had the
following distribution characteristics: mean 5 $12,071 6
$24,057, range $1,868–$303,659 and median 5 $7,286. There
were no significant cost differences between the randomization
groups stratified by procedural subgroups (Table 4).
Stroke and vascular complications. There were no signif-
icant differences between the triage angiography and conser-
vative groups in terms of stroke: 2 (2%) versus 2 (2%) (p 5
0.77). Each group had one hemorrhagic and one nonhemor-
rhagic stroke. Transient azotemia occurred in 2 (2%) versus 3
(3%) (p 5 0.81). Renal failure requiring dialysis did not
occur. Vascular complications requiring surgical repair oc-
curred in 1 (1%) versus 0 (0%) (p 5 0.55) (Table 2). There
was a trend for more transfusions in the triage angiography
arm (11 [10%] vs. 4 [5%], p 5 0.17), however, the majority
(12 of 15) of these transfusions occurred in the postopera-
tive period after CABG.
Time from admission to revascularization. Times from
symptom onset to emergency department arrival, angiography,
PTCA and CABG are given in Table 2. The mean time from
admission to any form of revascularization was 27 6 32 versus
88 6 98 h for the triage angiography and conservative groups,
respectively (p 5 0.0001). Similarly, the mean waiting times to
Table 4. Results
Endpoint
Triage Angiography
Group (n 5 111)
Conservative
Group (n 5 90) p Value
In-Hospital Clinical Endpoints
Confirmed AMI 57 (51%) 49 (54%) 0.81
Chest pain with ECG* or 3 (3%) 12 (13%) 0.004
Hemodynamic changes†
Chest pain without ECG or 9 (8%) 21 (23%) 0.003
Hemodynamic changes
Reinfarction 2 (2%) 0 (0%) 0.5
In-hospital death 1 (1%) 3 (3%) 0.3
Composite of recurrent ischemic events
with ECG or hemodynamic changes,
reinfarction or death
5 (5%) 12 (13%) 0.03
Composite of All Recurrent Ischemic
Events or Death
14 (13%) 31 (34%) 0.0002
Late Cardiac Events
Repeat hospitalization 25 (23%) 20 (22%) 0.9
Coronary angiography 14 (13%) 18 (20%) 0.2
PTCA overall 13 (12%) 9 (10%) 0.7
PTCA for restenosis 8 (4%) 3 (3%) 0.4
Developed CHF 9 (8%) 5 (6%) 0.5
CABG 2 (2%) 3 (3%) 0.5
Nonfatal MI 2 (2%) 2 (2%) 0.9
Death 11 (10%) 6 (7%) 0.4
Cumulative Endpoints
Repeat MI or reinfarction 4 (4%) 2 (2%) 0.9
Death 12 (11%) 9 (10%) 0.9
Composite of Repeat MI or Reinfarction
or Death
15 (14%) 11 (12%) 0.6
Economic Endpoints from Index
Hospitalization
Hospital length of stay (days)‡ 5 6 5 5 6 4 0.60
Hospital costs (1995 dollars) all patients§ $11,239 6 8,911 $9,251 6 8,010 0.10
Patients who ultimately underwent
angiography
$11,327 6 8,919 $11,731 6 8,954 0.77
Patients who underwent subsequent
PTCA
$12,562 6 8,503 $10,780 6 7,408 0.37
Patients who underwent CABG $21,511 6 7,986 $28,768 6 7,882 0.09
Patients who did not undergo angiography — $4,911 6 2,029 —
*Indicates ST segment elevation or depression or T-wave changes interpreted to be ischemic in etiology. †Indicates
hypertension or hypotension requiring a medical response from the attending physician staff. ‡After adjustment for
outliers beyond two standard deviations from the mean LOS of all patients (essentially excluded those patients with LOS
more than 27 d). §After adjustment for outliers with patients with hospital costs greater than 2 standard deviations from
the mean of the parent distribution (essentially excluded those patients with hospital charges greater than $60,184 in 1995
dollars).
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PTCA or CABG were shorter in the triage angiography group
(Fig. 2).
Late cardiac events. The median time from the index event
to follow-up was 21 months, with a minimum of 12 and a
maximum of 52 months. There were no significant differences
between the randomization arms with respect to repeat hospi-
talizations, subsequent angiography, late PTCA or late CABG
(Table 4, Fig. 3). Likewise, there were no differences in the
overall cumulative (from the time of initial presentation to
long-term follow-up) incidences of PTCA, CABG, recurrent
nonfatal AMI or all-cause death (Fig. 4). The composite
endpoint of cumulative nonfatal MI or death occurred in 15
(14%) versus 11 (12%) in the triage angiography and conser-
vative groups, p 5 0.6. Similarly, the Kaplan-Meier estimates
revealed no differences between the groups over the follow-up
period with respect to this endpoint (p 5 0.8) by the log rank
statistic (Fig. 5).
Bypass surgery mortality. Deaths after bypass surgery oc-
curred on the index hospitalization in 1/18 (6%) and 1/6 (17%)
(p 5 0.4) in the triage angiography and conservative groups,
respectively. Mortality after late CABG procedures performed
during the follow-up period was 0 of 2 (0%) and 1 of 3 (33%),
yielding an overall bypass surgery mortality rate of 1 of 20 (5%)
and 2 of 9 (22%) (p 5 0.22) in the two groups, respectively.
Putting all cases together, bypass surgery mortality accounted
for 3 of 21 (14%) of the deaths observed in this study.
Efficacy analysis. Because of the high crossover rate (60%)
in our trial, we performed an efficacy analysis with comparisons
made with respect to patients who received early revascular-
ization versus all others. Of the 201 subjects randomized, 97
(48%) received revascularization with PTCA or CABG on the
index hospitalization and 13 (7%) received revascularization
during the follow-up period (restenosis cases excluded), leav-
ing 91 (45%) who were treated medically without revascular-
ization. There were 21 versus 24 repeat hospitalizations, one
versus three recurrent MIs and nine versus eight deaths, in the
early revascularization group compared with all others. When
the late events were adjusted for ischemia-guided revascular-
ization, the comparisons above revealed 21 versus 11 hospital-
izations (RR 5 1.8, CI 5 0.9–3.5, p 5 .08), one versus one
recurrent MIs and nine versus eight deaths (all other p . 0.10) for
the early revascularization versus medically treated groups (with-
out revascularization). In addition, survival analysis by revas-
cularization status showed no difference between early versus
late or any versus none with the log rank test (all p . 0.10).
Discussion
Studies of invasive versus conservative management in
acute syndromes. Acute coronary syndromes ineligible for
thrombolysis are a common cause for hospitalization and
subsequent morbidity in terms of cardiac events in the United
States (34). This trial is now one of three such studies to
examine the issue of timing of angiography and revasculariza-
tion. In the TIMI IIIB trial, early angiography occurred
between 18 and 48 hours (reported mean of 1.5 d or 36 h) in
373 subjects versus 371 who received conservative care (non-
thrombolytic arms of the factorial) (20). In the partially
Figure 3. Late events that occurred after hospital discharge in 201
patients randomized to triage angiography (solid columns; n 5 111) or
conservative care (striped columns; n 5 90). Despite more early
revascularization procedures during the hospitalization, there were no
differences observed in long-term outcomes at a median of 21 months,
including rehospitalization after discharge (Hosp.), coronary angiog-
raphy during the follow-up period (Cath.), nonfatal myocardial infarc-
tion (MI) or death from any cause (Death).
Figure 2. Time from hospital admission to revascularization with
either PTCA or CABG in 97 of 201 patients randomized to conserva-
tive care (striped columns; n 5 33) or triage angiography (solid
columns; n 5 64) within 24 h of admission.
Figure 4. Cumulative revascularization and cardiac events in 201
patients randomized to triage angiography (solid columns; n 5 111) or
conservative care (striped columns; n 5 90) over a median follow-up of
21 months. See definitions in the legend for Figure 3.
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reported Veterans Administration Non-Q-Wave Strategies
In-Hospital (VANQWISH) trial, early angiography was car-
ried out at a median of 48 h after hospital admission in 462
versus 458 who received ischemia-guided care (35–37). Our
trial is the first to employ angiography as a triage mechanism
where the procedure was performed as early as possible to the
presentation of symptoms and entry into the medical system,
via community hospital or tertiary center.
The TIMI IIIB, VANQWISH and MATE trials all exhib-
ited the difficulty in adhering to a conservative protocol arm,
with in-hospital crossover to angiography rates of 67%, 24%
and 60% respectively (20,21,35–37). The VANQWISH trial
had the best protocol adherence, probably attributable to the
fact that subjects were allowed to be enrolled after 24 h and
represented a more stable group with completed non-q-wave
infarctions (35–37). In fact, the VANQWISH protocol re-
quired subjects to be enrolled after 24 h and have no evidence
of recurrent ischemia or hemodynamic compromise (38). All
three trials demonstrated the principle that mandated angiog-
raphy will lead to earlier revascularization by PTCA or CABG.
In addition, the MATE trial demonstrated the concept that
reducing the time from the index event to angiography limits
the opportunity for recurrent ischemic events to occur. This
reduction in recurrent ischemia, however, did not appear to
bear on the long-term result of all-cause mortality in the
treatment groups.
Invasive strategies and cardiac enzymes. Our finding of
overall 20% of culprit vessels being occluded at the time of
angiography (33 of 163 of cases where angiography was
performed) is consistent with the work of Kulick and Rahim-
toola, which suggests that if reperfusion could occur early
enough, a benefit may be observed (39). Furthermore, analyses
from multiple trials of acute coronary syndromes indicate that
even small infarctions detected by troponin testing and not by
traditional CK measurements indicate a poorer short-term
prognosis (28–32). These observations led to the notion that
early revascularization would be beneficial in such patients.
Troponin testing was not used in the early angiography deci-
sion in the TIMI IIIB, VANQWISH or the MATE study, and
perhaps this or some other triage tool should be tested next in
a randomized trial to determine which strategy, if any, is
superior to the conventional, ischemia-guided treatment of
acute ischemic syndromes (20,21,35–37).
Clinical effectiveness of early angiography. The immediate
clinical utility of coronary angiography has probably been
understated in all three trials that led to a focus on long-term
mortality as the ultimate endpoint. The advantage of the
angiogram over conventional triage tools is the decision-
enhancing capability provided to the physician. Knowledge of
the coronary anatomy, left ventricular function and filling
pressures permits triage of patients to medical therapy, imme-
diate percutaneous intervention or bypass surgery. Further-
more, the triage angiogram helps provide definitive disposition
of discharge to home, telemetry unit or coronary care unit.
These benefits have been difficult to quantitate in previous
studies of acute coronary syndromes management (39,40). The
shortened time to revascularization and reduction in recurrent
Figure 5. Kaplan-Meier curves for freedom from recurrent myocardial
infarction (MI) or death in 201 patients randomized to triage angiog-
raphy (solid line; n 5 111) or conservative care (broken line; n 5 90)
over a median follow-up of 21 months. The diamonds indicate
censored patients. p 5 0.8.
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ischemic events both indirectly reflect the enhanced clinical
efficiency of the triage angiography strategy.
Triage angiography benefited those patients encaptured in
our study who had noncoronary chest discomfort syndromes
(proved angiographically in 13%). These patients accounted
for 44% of those patients able to be discharged from the
hospital in 2 d or less. Conversely, only 17% of the conservative
group patients were able to be discharged to home in less than
2 d. This was attributable to the common delays of “rule-out
AMI” enzymatic protocols, scheduling of noninvasive testing
and physician review of the data (41). In addition, triage
angiography appeared to be safe in that no increases in stroke,
vascular or renal complications were observed.
Limitations of our study, common to studies of this nature,
include the impossibility of blindedness, the interim analysis
performed at an “unblocked” level of the randomization and
the high utilization of angiography in the conservative arm.
The former two could have favored the triage angiography
group, whereas the latter clearly favored the conservative
group in terms of primary outcome assessment. The random-
ization held in terms of major confounders such as age, sex and
previous history of coronary disease, and thus these factors are
unlikely to have influenced the observed outcome. Our study,
like many randomized trials, ultimately selected a relatively
low-risk study group with an in-hospital mortality rate of 2%
and a cumulative 10% mortality rate at 21 months of follow-
up. These rates are considerably less than the retrospective
series reported by Cragg and colleagues and Behar and
coworkers, and reflect the inherently difficult inclusion of
high-risk patients into clinical trials with invasive versus
conservative randomizations (26,27). Finally, this study like
others with logistically challenging randomization protocols,
including TIMI IIIB and VANQWISH, was not powered to
show a long-term recurrent myocardial infarction or mor-
tality difference in treatment allocation (20,21,35–37). A
study powered (80% power, a 5 0.05) to show at least a 25%
reduction in mortality would require approximately 8,000
subjects, far more than the combined 2,594 (1,865 not
exposed to thrombolytics) available for analysis from TIMI
IIIB, VANQWISH and MATE (20,21,35–37).
Conclusions
In conclusion, triage angiography applied to those patients
with acute coronary syndromes considered to be ineligible for
thrombolytic therapy provides a diagnostic and treatment
platform that reduces the composition of recurrent ischemic
events or in-hospital death, reduces the waiting time for
definitive revascularization and is not associated with increased
costs over conventional medical therapy and observation.
These short-term benefits, however, do not translate into
measurable long-term differences in the rates of rehospitaliza-
tion, repeat angiography, late revascularization, recurrent
myocardial infarction or death.
We are indebted to James A. Goldstein, MD, Gerald C. Timmis, MD, Gregg W.
Stone, MD, and W. Douglas Weaver, MD. This group provided critical review
and support to the trial. We would also like to express gratitude to Kristin B.
McCabe, BA, who assisted in the final preparation of this manuscript.
Appendix
The following centers and investigators contributed to patient
recruitment in the MATE Trial: William Beaumont Hospital
(P.A.M., M.G., C.L.G., W.W.O.), n 5 168; Botsford Hospital
(R.J.S.), n 5 15; Riverside Hospital (F.R.), n 5 10; and Providence
Hospital (S.D.), n 5 8.
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